Gary L. Freed, MD, MPH

The second in a year-long series of commentary reviewing topics published in Contemporary Pediatrics 25 years ago.

The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.